Stay updated on Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.

Latest updates to the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page
- Check6 days agoChange DetectedThe page has removed a citation regarding health-related quality of life in advanced gastric cancer, which included an erratum reference.SummaryDifference0.2%
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.0%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedThe page has been updated to include new identifiers related to the study on gastric adenocarcinoma, while significant details about the study's design and participant criteria have been removed.SummaryDifference13%
- Check42 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check49 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check85 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Paclitaxel in Gastric Cancer Clinical Trial page.